StephenGEllisMD

Cardiology • Cleveland, OH

Adult Congenital Heart Disease, Interventional Cardiology

Professor of Medicine Section Head/Interventioanl Cardiology Cleveland Clinic

Join to view full profile

Dr. Ellis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ellis' full profile

Already have an account?

Office
9500 Euclid Ave
Cleveland, OH 44195
Phone+1 216-445-6712

Fax+1 216-445-6714

Education & Training

Emory University School of MedicineFellowship, Cardiovascular Disease, 1985 - 1986
Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 1982 - 1985
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1981 - 1982
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1978 - 1981
David Geffen School of Medicine at UCLAClass of 1978

Certifications & Licensure

OH State Medical License 1991 - 2027
CA State Medical License 2002 - 2026
NY State Medical License 2002 - 2020
IL State Medical License 2002 - 2017
PA State Medical License 2002 - 2016
MI State Medical License 1986 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Northern Ohio Live Castle Connolly, 2006
Fellow (FACC) American College of Cardiology
Join now to see all

Clinical Trials

A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction
Completed
Phase 1, Phase 2
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis Start of enrollment: 2003 Jun 01
Completed
Phase 2, Phase 3
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent Start of enrollment: 2002 Mar 01
Completed
Phase 2, Phase 3
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions Start of enrollment: 2003 Feb 01
Completed
Phase 2, Phase 3
Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal Start of enrollment: 2007 Aug 01
Completed
ABSORB III Randomized Controlled Trial (RCT) Start of enrollment: 2012 Dec 01
Completed
Not Applicable
Absorb IV Randomized Controlled Trial Start of enrollment: 2014 Jul 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

2 citations
Developments and Controversies in Invasive Diagnosis of Coronary Microvascular Dysfunction in Angina With Nonobstructive Coronary Arteries.
Kara J Denby, Mohammad Zmaili, Sudarshana Datta, Thomas Das, Stephen Ellis
Mayo Clinic Proceedings. 2024-09-01
Optimizing the Use of Artificial Intelligence in Cardiology in 2024.
Stephen G Ellis, Michael W Kattan
JACC. Cardiovascular Interventions. 2024-07-22
2 citations
Coronary spasm and vasomotor dysfunction as a cause of MINOCA.
Zachary S Yaker, A Michael Lincoff, Leslie Cho, Stephen G Ellis, Khaled M Ziada
Eurointervention. 2024-01-15

Abstracts/Posters

[Board 005] Ethnic Differences in 10 Year Clinical Outcomes After Drug Eluting Stenting: Why Do African Americans Fare So Poorly?
Stephen Ellis, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/16/2019

Press Mentions

ABSORB III: 5-Year Results Offer Renewed Hope for Bioresorbable StentsSeptember 26th, 2019
EuroCTO CASTLE: Prediction Model for CTO PCI Success Shows Good Discriminating AbilityFebruary 4th, 2019
Revascularization for Silent Ischemia Linked to Better OutcomesJanuary 17th, 2019
Join now to see all

Professional Memberships

American College of Cardiology - ACC
Member